Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CAR.k.28 cells + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CAR.k.28 cells||ATLCAR.k.28|ATLCAR.kappa.28||CAR.k.28 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor targeting the Kappa-light chain antibody linked to CD28 endodomain, which potentially induces cytotoxicity against Kappa-positive tumor cells (PMID: 16926291).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04223765||Phase I||Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine||Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma||Not yet recruiting|